Literature DB >> 19593635

Distinct gene mutation profiles among luminal-type and basal-type breast cancer cell lines.

Antoinette Hollestelle1, Jord H A Nagel, Marcel Smid, Suzanne Lam, Fons Elstrodt, Marijke Wasielewski, Ser Sue Ng, Pim J French, Justine K Peeters, Marieke J Rozendaal, Muhammad Riaz, Daphne G Koopman, Timo L M Ten Hagen, Bertie H C G M de Leeuw, Ellen C Zwarthoff, Amina Teunisse, Peter J van der Spek, Jan G M Klijn, Winand N M Dinjens, Stephen P Ethier, Hans Clevers, Aart G Jochemsen, Michael A den Bakker, John A Foekens, John W M Martens, Mieke Schutte.   

Abstract

Breast cancer has for long been recognized as a highly diverse tumor group, but the underlying genetic basis has been elusive. Here, we report an extensive molecular characterization of a collection of 41 human breast cancer cell lines. Protein and gene expression analyses indicated that the collection of breast cancer cell lines has retained most, if not all, molecular characteristics that are typical for clinical breast cancers. Gene mutation analyses identified 146 oncogenic mutations among 27 well-known cancer genes, amounting to an average of 3.6 mutations per cell line. Mutations in genes from the p53, RB and PI3K tumor suppressor pathways were widespread among all breast cancer cell lines. Most important, we have identified two gene mutation profiles that are specifically associated with luminal-type and basal-type breast cancer cell lines. The luminal mutation profile involved E-cadherin and MAP2K4 gene mutations and amplifications of Cyclin D1, ERBB2 and HDM2, whereas the basal mutation profile involved BRCA1, RB1, RAS and BRAF gene mutations and deletions of p16 and p14ARF. These subtype-specific gene mutation profiles constitute a genetic basis for the heterogeneity observed among human breast cancers, providing clues for their underlying biology and providing guidance for targeted pharmacogenetic intervention in breast cancer patients.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 19593635     DOI: 10.1007/s10549-009-0460-8

Source DB:  PubMed          Journal:  Breast Cancer Res Treat        ISSN: 0167-6806            Impact factor:   4.872


  136 in total

1.  Update on the molecular profile of the MDA-MB-453 cell line as a model for apocrine breast carcinoma studies.

Authors:  Semir Vranic; Zoran Gatalica; Zhao-Yi Wang
Journal:  Oncol Lett       Date:  2011-11       Impact factor: 2.967

Review 2.  Wnt signaling in mammary glands: plastic cell fates and combinatorial signaling.

Authors:  Caroline M Alexander; Shruti Goel; Saja A Fakhraldeen; Soyoung Kim
Journal:  Cold Spring Harb Perspect Biol       Date:  2012-10-01       Impact factor: 10.005

Review 3.  Molecular basis for therapy resistance.

Authors:  Per E Lønning
Journal:  Mol Oncol       Date:  2010-04-24       Impact factor: 6.603

4.  The transcription factor ZNF217 is a prognostic biomarker and therapeutic target during breast cancer progression.

Authors:  Laurie E Littlepage; Adam S Adler; Hosein Kouros-Mehr; Guiqing Huang; Jonathan Chou; Sheryl R Krig; Obi L Griffith; James E Korkola; Kun Qu; Devon A Lawson; Qing Xue; Mark D Sternlicht; Gerrit J P Dijkgraaf; Paul Yaswen; Hope S Rugo; Colleen A Sweeney; Colin C Collins; Joe W Gray; Howard Y Chang; Zena Werb
Journal:  Cancer Discov       Date:  2012-05-10       Impact factor: 39.397

5.  Association of RB/p16-pathway perturbations with DCIS recurrence: dependence on tumor versus tissue microenvironment.

Authors:  Agnieszka K Witkiewicz; Dayana B Rivadeneira; Adam Ertel; Jessica Kline; Terry Hyslop; Gordon F Schwartz; Paolo Fortina; Erik S Knudsen
Journal:  Am J Pathol       Date:  2011-07-12       Impact factor: 4.307

6.  A Transcriptionally Definable Subgroup of Triple-Negative Breast and Ovarian Cancer Samples Shows Sensitivity to HSP90 Inhibition.

Authors:  Kevin Shee; Jason D Wells; Matthew Ung; Riley A Hampsch; Nicole A Traphagen; Wei Yang; Stephanie C Liu; Megan A Zeldenrust; Liewei Wang; Krishna R Kalari; Jia Yu; Judy C Boughey; Eugene Demidenko; Arminja N Kettenbach; Chao Cheng; Matthew P Goetz; Todd W Miller
Journal:  Clin Cancer Res       Date:  2019-09-26       Impact factor: 12.531

7.  Combined PI3K/mTOR and MEK inhibition provides broad antitumor activity in faithful murine cancer models.

Authors:  Patrick J Roberts; Jerry E Usary; David B Darr; Patrick M Dillon; Adam D Pfefferle; Martin C Whittle; James S Duncan; Soren M Johnson; Austin J Combest; Jian Jin; William C Zamboni; Gary L Johnson; Charles M Perou; Norman E Sharpless
Journal:  Clin Cancer Res       Date:  2012-08-07       Impact factor: 12.531

8.  The cell-surface anchored serine protease TMPRSS13 promotes breast cancer progression and resistance to chemotherapy.

Authors:  Andrew S Murray; Thomas E Hyland; Kimberley E Sala-Hamrick; Jacob R Mackinder; Carly E Martin; Lauren M Tanabe; Fausto A Varela; Karin List
Journal:  Oncogene       Date:  2020-08-31       Impact factor: 9.867

9.  Combined p53- and PTEN-deficiency activates expression of mesenchyme homeobox 1 (MEOX1) required for growth of triple-negative breast cancer.

Authors:  Mari Gasparyan; Miao-Chia Lo; Hui Jiang; Chang-Ching Lin; Duxin Sun
Journal:  J Biol Chem       Date:  2020-05-28       Impact factor: 5.157

10.  Human breast cancer cell lines co-express neuronal, epithelial, and melanocytic differentiation markers in vitro and in vivo.

Authors:  Qingbei Zhang; Hanli Fan; Jikun Shen; Robert M Hoffman; H Rosie Xing
Journal:  PLoS One       Date:  2010-03-16       Impact factor: 3.240

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.